96 related articles for article (PubMed ID: 19544194)
1. QSAR models for P450 (2D6) substrate activity.
Ringsted T; Nikolov N; Jensen GE; Wedebye EB; Niemelä J
SAR QSAR Environ Res; 2009; 20(3-4):309-25. PubMed ID: 19544194
[TBL] [Abstract][Full Text] [Related]
2. Identification of cytochrome P450 2D6 and 2C9 substrates and inhibitors by QSAR analysis.
Jónsdóttir SÓ; Ringsted T; Nikolov NG; Dybdahl M; Wedebye EB; Niemelä JR
Bioorg Med Chem; 2012 Mar; 20(6):2042-53. PubMed ID: 22364953
[TBL] [Abstract][Full Text] [Related]
3. QSAR models for anti-androgenic effect--a preliminary study.
Jensen GE; Nikolov NG; Wedebye EB; Ringsted T; Niemela JR
SAR QSAR Environ Res; 2011 Mar; 22(1-2):35-49. PubMed ID: 21391140
[TBL] [Abstract][Full Text] [Related]
4. Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
Kemp CA; Flanagan JU; van Eldik AJ; Maréchal JD; Wolf CR; Roberts GC; Paine MJ; Sutcliffe MJ
J Med Chem; 2004 Oct; 47(22):5340-6. PubMed ID: 15481972
[TBL] [Abstract][Full Text] [Related]
5. A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series.
Vaz RJ; Nayeem A; Santone K; Chandrasena G; Gavai AV
Bioorg Med Chem Lett; 2005 Sep; 15(17):3816-20. PubMed ID: 15993593
[TBL] [Abstract][Full Text] [Related]
6. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108.
de Groot MJ; Vermeulen NP; Kramer JD; van Acker FA; Donné-Op den Kelder GM
Chem Res Toxicol; 1996; 9(7):1079-91. PubMed ID: 8902262
[TBL] [Abstract][Full Text] [Related]
7. Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6.
Jones BC; Hyland R; Ackland M; Tyman CA; Smith DA
Drug Metab Dispos; 1998 Sep; 26(9):875-82. PubMed ID: 9733666
[TBL] [Abstract][Full Text] [Related]
8. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.
Wang B; Yang LP; Zhang XZ; Huang SQ; Bartlam M; Zhou SF
Drug Metab Rev; 2009; 41(4):573-643. PubMed ID: 19645588
[TBL] [Abstract][Full Text] [Related]
9. Probing small-molecule binding to cytochrome P450 2D6 and 2C9: An in silico protocol for generating toxicity alerts.
Rossato G; Ernst B; Smiesko M; Spreafico M; Vedani A
ChemMedChem; 2010 Dec; 5(12):2088-101. PubMed ID: 21038340
[TBL] [Abstract][Full Text] [Related]
10. Classification of cytochrome p(450) activities using machine learning methods.
Hammann F; Gutmann H; Baumann U; Helma C; Drewe J
Mol Pharm; 2009; 6(6):1920-6. PubMed ID: 19813762
[TBL] [Abstract][Full Text] [Related]
11. Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate.
McConnachie L; Bodor M; Kowdley K; Levy A; Tung B; Thummel K; Phillips B; Bajpai M; Chi V; Esmay JD; Shen DD; Ho RJ
Clin Pharmacol Ther; 2004 Apr; 75(4):282-97. PubMed ID: 15060507
[TBL] [Abstract][Full Text] [Related]
12. Optimizing QSAR models for predicting ligand binding to the drug-metabolizing cytochrome P450 isoenzyme CYP2D6.
Saraceno M; Massarelli I; Imbriani M; James TL; Bianucci AM
Chem Biol Drug Des; 2011 Aug; 78(2):236-51. PubMed ID: 21575140
[TBL] [Abstract][Full Text] [Related]
13. Recursive partitioning for the prediction of cytochromes P450 2D6 and 1A2 inhibition: importance of the quality of the dataset.
Burton J; Ijjaali I; Barberan O; Petitet F; Vercauteren DP; Michel A
J Med Chem; 2006 Oct; 49(21):6231-40. PubMed ID: 17034129
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites.
Ekins S; de Groot MJ; Jones JP
Drug Metab Dispos; 2001 Jul; 29(7):936-44. PubMed ID: 11408357
[TBL] [Abstract][Full Text] [Related]
15. QSAR studies of CYP2D6 inhibitor aryloxypropanolamines using 2D and 3D descriptors.
Roy PP; Roy K
Chem Biol Drug Des; 2009 Apr; 73(4):442-55. PubMed ID: 19291105
[TBL] [Abstract][Full Text] [Related]
16. A refined substrate model for human cytochrome P450 2D6.
de Groot MJ; Bijloo GJ; Martens BJ; van Acker FA; Vermeulen NP
Chem Res Toxicol; 1997 Jan; 10(1):41-8. PubMed ID: 9074801
[TBL] [Abstract][Full Text] [Related]
17. Quantitative structure-activity relationship (QSAR) analysis of the inhibitory effects of furanocoumarin derivatives on cytochrome P450 3A activities.
Uesawa Y; Mohri K
Pharmazie; 2010 Jan; 65(1):41-6. PubMed ID: 20187577
[TBL] [Abstract][Full Text] [Related]
18. Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling.
Valerio LG; Arvidson KB; Chanderbhan RF; Contrera JF
Toxicol Appl Pharmacol; 2007 Jul; 222(1):1-16. PubMed ID: 17482223
[TBL] [Abstract][Full Text] [Related]
19. Quantitative structure-activity relationship modeling of the toxicity of organothiophosphate pesticides to Daphnia magna and Cyprinus carpio.
Zvinavashe E; Du T; Griff T; van den Berg HH; Soffers AE; Vervoort J; Murk AJ; Rietjens IM
Chemosphere; 2009 Jun; 75(11):1531-8. PubMed ID: 19376559
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues.
Hutzler JM; Walker GS; Wienkers LC
Chem Res Toxicol; 2003 Apr; 16(4):450-9. PubMed ID: 12703961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
